Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing"

Clin Cancer Res. 2011 Oct 15;17(20):10.1158/1078-0432.CCR-11-1504. doi: 10.1158/1078-0432.CCR-11-1504.
No abstract available